v3.25.2
Shareholders' Equity (Tables)
12 Months Ended
Jun. 30, 2025
Shareholders' Equity [Abstract]  
Schedule of Company’s Warrants, Pre-Funded Warrants and Options

A summary of the share options granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary is as follows:

 

   Year ended June 30, 2024 
   Number   Weighted
average
exercise price
   Weighted
average
remaining
contractual
terms
(in years)
   Aggregate
intrinsic
value price
 
Share options outstanding at beginning of period   8,100   $7.44    6.24    29 
Share options granted   9,375   $4.40    4.56    13 
Share options outstanding at end of the period   17,475   $5.80    4.87   $42 
Share options exercisable at the end of the period   8,100   $7.41    5.24   $29 
Share options unvested   9,375   $4.40    4.56    13 
Share options vested and expected to vest at the end of the period   17,475   $5.80    4.87   $42 

 

   Year ended June 30, 2025 
   Number   Weighted
average
exercise price
   Weighted
average
remaining
contractual
terms
(in years)
   Aggregate
intrinsic
value price
 
Share options outstanding at beginning of period   17,475   $5.80    4.87   $42 
Share options forfeited   (6,720)  $5.10    
-
    
-
 
Share options outstanding and exercisable at end of the period   10,755   $6.23    4.23   $24 
Share options vested and expected to vest at the end of the period   10,755   $6.23    4.23   $24 

A summary of the share options granted to CEO and to a former directors under the Plans by Pluri Inc. and its Subsidiary is as follows:

 

   Year ended June 30, 2024 
   Number   Weighted
average
exercise price
   Weighted
average
remaining
contractual
terms
(in years)
 
Share options outstanding at the beginning of the period   229,353   $15.20    3.47 
Share options granted   12,500   $6.08    6.73 
Share options forfeited   (1,562)  $6.08    
-
 
Share options outstanding at the end of the period   240,291   $14.82    2.42 
Share options vested and exercisable at the end of the period   240,291   $14.82    2.42 

 

   Year ended June 30, 2025 
   Number   Weighted
average
exercise price
   Weighted
average
remaining
contractual
terms
(in years)
 
Share options outstanding at the beginning of the period   240,291   $14.82    2.42 
Share options outstanding at the end of the period   240,291   $14.82    1.42 
Share options vested and exercisable at the end of the period   240,291   $14.82    1.42 
Schedule of Black-Scholes Option-Pricing Model Using the Following Assumptions

The fair value of each option was estimated as of the date of grant using the Black-Scholes option-pricing model using the following assumptions:

 

   2024 
Underlying value of common shares ($)   4.40-6.08 
Exercise price ($)   4.40-6.08 
Expected historical volatility (%)   78.44 
Expected terms of the option (years)   5-7 
Risk-free interest rate (%)   4.04-4.13 
Schedule of Activity Related to Unvested RSUs Granted

The following table summarizes the activity related to unvested RSUs granted to employees and directors under the Plans by Pluri Inc. and its Subsidiary, for the years ended June 30, 2025 and 2024:

 

   Year ended June 30, 
   2025   2024 
   Number 
Unvested at the beginning of period   353,134    207,199 
Granted   618,515    395,327 
Forfeited   (29,018)   (132,400)
Vested   (307,868)   (116,992)
Unvested at the end of the period   634,763    353,134 
Expected to vest after the end of period   583,844    319,533 

The following table summarizes the activity related to unvested RSUs and RS granted to non-employee consultants under the Plans by Pluri Inc. and its Subsidiary for the years ended June 30, 2025 and 2024:

 

   Year ended June 30, 
   2025   2024 
   Number 
Unvested at the beginning of period   4,802    2,500 
Granted   54,269    27,270 
Vested   (34,520)   (24,968)
Unvested at the end of the period   24,551    4,802 
Expected to vest after the end of period   24,551    4,802 
Schedule of Expenses Related to RSUs Granted

Total compensation expenses related to RSUs and RS granted by Pluri Inc. and its Subsidiary were recorded as follows:

 

   Year ended June 30, 
   2025   2024 
Research and development expenses  $463   $316 
General and administrative expenses   1,517    1,428 
   $1,980   $1,744 
Schedule of Company’s Warrants, Pre-Funded Warrants and Options Summary of the Company’s warrants, pre-funded warrants and options:
   June 30, 2025 
Warrants / Pre-Funded Warrants / Options  Weighted average exercise
price per
share
   Options,
pre-funded warrants and
warrants
for common
shares
   Options,
pre-funded warrants and
warrants
exercisable
for common
shares
   Weighted
average
remaining
contractual
terms
(in years)
 
Warrants:  $8.24    697,485    697,485    0.55 
   $8.40    258,565    258,565    0.51 
   $8.48    29,688    29,688    0.47 
   $8.72    16,875    16,875    0.49 
   $8.96    16,875    16,875    0.50 
   $5.57    84,599    84,599    3.00 
   $5.57    45,553    45,553    2.72 
Total warrants        1,149,640    1,149,640      
                     
Pre-Funded Warrants:  $
-
    1,002,169    1,002,169    3.00 
Total pre-funded warrants        1,002,169    1,002,169      
                     
 Options:  $6.23    10,755    10,755    4.23 
   $8.96    41,853    41,853    1.04 
   $12.48    62,500    62,500    1.25 
   $16.64    62,500    62,500    1.25 
   $20.80    62,500    62,500    1.25 
   $6.08    10,938    10,938    5.73 
Total options        251,046    251,046      
Total Warrants, Pre-Funded Warrants and Options        2,402,855    2,402,855